| scholarly article | Q13442814 |
| P50 | author | Jeffrey Lipman | Q53678222 |
| P2093 | author name string | Susan E Tett | |
| Megan E DelDot | |||
| P2860 | cites work | APACHE II: a severity of disease classification system | Q29547729 |
| The therapeutic monitoring of antimicrobial agents. | Q33540451 | ||
| Symposium on antimicrobial agents--Part XII. Vancomycin | Q33733570 | ||
| Renal replacement therapies | Q33825816 | ||
| Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. | Q34480866 | ||
| Pharmacokinetics of vancomycin in patients with various degrees of renal function | Q35758814 | ||
| Vancomycin: an update | Q39746652 | ||
| Pharmacokinetics of continuous renal replacement therapy | Q40434373 | ||
| Pharmacokinetic Optimisation of Vancomycin Therapy | Q40467559 | ||
| Anti-infective treatment in intensive care: the role of glycopeptides | Q40495770 | ||
| Glycopeptides and nephrotoxicity | Q40495778 | ||
| Clinical pharmacokinetics during continuous haemofiltration | Q40694502 | ||
| Renal replacement therapy for the critically ill--precarious progress. Part II. Technical aspects and clinical application | Q40721560 | ||
| Renal replacement therapy for the critically ill--precarious progress. Part I. Definitions and physiological aspects | Q40725084 | ||
| Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations | Q40913162 | ||
| Drug administration in critically ill patients with acute renal failure. | Q40953739 | ||
| A primer on continuous renal replacement therapy for critically ill patients | Q41734642 | ||
| Continuous versus intermittent renal replacement therapy in the intensive care unit | Q41758102 | ||
| Pharmacokinetics of vancomycin during continuous hemodiafiltration | Q42608683 | ||
| Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients | Q42613191 | ||
| Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration | Q43634387 | ||
| Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration | Q44019964 | ||
| Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. | Q47957828 | ||
| Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. | Q52300395 | ||
| Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance | Q67781827 | ||
| Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis | Q67858796 | ||
| Disposition of vancomycin during hemofiltration | Q69615894 | ||
| Vancomycin disposition during continuous arteriovenous hemofiltration | Q69649389 | ||
| Antimicrobial prescribing in patients on haemofiltration | Q71069675 | ||
| Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function | Q71108839 | ||
| Vancomycin redistribution: dosing recommendations following high-flux hemodialysis | Q72290128 | ||
| Vancomycin | Q72336044 | ||
| Pharmacokinetics of vancomycin when administered during high flux hemodialysis | Q77115745 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| vancomycin | Q424027 | ||
| hemodiafiltration | Q3144940 | ||
| P304 | page(s) | 259-268 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration | |
| P478 | volume | 58 |
| Q92170063 | A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy |
| Q35504097 | A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics |
| Q38261172 | Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much". |
| Q41379961 | Antibiotic dosing for renal function disorders and continuous renal replacement therapy |
| Q36257693 | Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy |
| Q37846092 | Antibiotic dosing in critically ill patients with acute kidney injury |
| Q37461431 | Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis |
| Q79303293 | Are higher vancomycin doses needed in ventricle-external shunted patients? |
| Q54957598 | Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation. |
| Q93046395 | Differences in Vancomycin Clearance between Trauma and Medical Intensive Care Unit Patients |
| Q33681401 | Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers |
| Q38107537 | Drug absorption, distribution, metabolism and excretion considerations in critically ill adults |
| Q38000242 | Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. |
| Q37008814 | Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy |
| Q79429283 | Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients |
| Q36652824 | Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: A Case Report. |
| Q42653979 | Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration |
| Q36048276 | Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references |
| Q37957195 | Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy |
| Q42947354 | Questionnaire surveying nephrologists on drug dose adjustment in patients with impaired kidney function |
| Q35942407 | SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients |
| Q37978648 | Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. |
| Q38687487 | The Nephrotoxicity of Vancomycin |
| Q46817846 | The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters |
| Q34026240 | Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation |
| Q42177195 | Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). |
| Q38258649 | Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. |
| Q35763971 | Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough? |
Search more.